Recently approved medications for resistant hypertension, uncomplicated UTIs and menopausal hot flashes show potential as ...

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of ...

The FDA has approved Zynyz (retifanlimab-dlwr) to treat patients with squamous cell carcinoma of the anal canal.

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs ... for the treatment of cUTIs in adults, including severe kidney ...

and urinary tract infections. According to the company’s safety information, doctors must advise their patients about using effective contraception during the therapy as the new treatment can ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...